• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康经济评估:方法学入门。

Health economic assessment: a methodological primer.

机构信息

Research Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium.

出版信息

Int J Environ Res Public Health. 2009 Dec;6(12):2950-66. doi: 10.3390/ijerph6122950. Epub 2009 Nov 27.

DOI:10.3390/ijerph6122950
PMID:20049237
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2800325/
Abstract

This review article aims to provide an introduction to the methodology of health economic assessment of a health technology. Attention is paid to defining the fundamental concepts and terms that are relevant to health economic assessments. The article describes the methodology underlying a cost study (identification, measurement and valuation of resource use, calculation of costs), an economic evaluation (type of economic evaluation, the cost-effectiveness plane, trial- and model-based economic evaluation, discounting, sensitivity analysis, incremental analysis), and a budget impact analysis. Key references are provided for those readers who wish a more advanced understanding of health economic assessments.

摘要

这篇综述文章旨在介绍卫生技术健康经济评估的方法学。本文注重于定义与健康经济评估相关的基本概念和术语。文章描述了成本研究(资源利用的识别、测量和评估,成本的计算)、经济评估(经济评估的类型、成本效果平面、基于试验和模型的经济评估、贴现、敏感性分析、增量分析)和预算影响分析的基本方法。对于那些希望更深入了解健康经济评估的读者,本文提供了关键参考文献。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31c8/2800325/d861aa59bac8/ijerph-06-02950f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31c8/2800325/33da19e4f692/ijerph-06-02950f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31c8/2800325/78d2071778d1/ijerph-06-02950f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31c8/2800325/b978649a1806/ijerph-06-02950f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31c8/2800325/d861aa59bac8/ijerph-06-02950f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31c8/2800325/33da19e4f692/ijerph-06-02950f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31c8/2800325/78d2071778d1/ijerph-06-02950f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31c8/2800325/b978649a1806/ijerph-06-02950f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31c8/2800325/d861aa59bac8/ijerph-06-02950f4.jpg

相似文献

1
Health economic assessment: a methodological primer.健康经济评估:方法学入门。
Int J Environ Res Public Health. 2009 Dec;6(12):2950-66. doi: 10.3390/ijerph6122950. Epub 2009 Nov 27.
2
Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.预算影响分析——良好实践原则:ISPOR 2012 预算影响分析良好实践 II 工作组报告。
Value Health. 2014 Jan-Feb;17(1):5-14. doi: 10.1016/j.jval.2013.08.2291. Epub 2013 Dec 13.
3
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.预算影响分析良好实践原则:ISPOR良好研究实践特别工作组——预算影响分析报告
Value Health. 2007 Sep-Oct;10(5):336-47. doi: 10.1111/j.1524-4733.2007.00187.x.
4
Improving the usefulness of budget impact analyses: a U.S. payer perspective.提高预算影响分析的实用性:美国支付方视角
Value Health. 2014 Jan-Feb;17(1):3-4. doi: 10.1016/j.jval.2013.09.007.
5
Resource modelling: the missing piece of the HTA jigsaw?资源建模:卫生技术评估拼图中缺失的一块?
Pharmacoeconomics. 2015 Mar;33(3):193-203. doi: 10.1007/s40273-014-0228-9.
6
Discounting and decision making in the economic evaluation of health-care technologies.医疗保健技术经济评估中的折扣和决策。
Health Econ. 2011 Jan;20(1):2-15. doi: 10.1002/hec.1612. Epub 2010 May 12.
7
[Economic evaluation of healthcare technologies: an introduction for physicians].[医疗技术的经济评估:给医生的介绍]
Rev Neurol. 2011 Jul 16;53(2):107-15.
8
Budget impact analysis.预算影响分析。
Epidemiol Serv Saude. 2017 Apr-Jun;26(2):421-424. doi: 10.5123/S1679-49742017000200020.
9
Spanish recommendations on economic evaluation of health technologies.西班牙卫生技术经济评价建议。
Eur J Health Econ. 2010 Oct;11(5):513-20. doi: 10.1007/s10198-010-0244-4. Epub 2010 Apr 20.
10
Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine.对第二届卫生与医学成本效益专题小组的建议不予理会。
Pharmacoeconomics. 2017 Jan;35(1):5-13. doi: 10.1007/s40273-016-0482-0.

引用本文的文献

1
Barriers and Enablers of Value-Based Procurement in Dutch Healthcare Providers.荷兰医疗服务提供商基于价值的采购的障碍与推动因素
Int J Health Policy Manag. 2025;14:8514. doi: 10.34172/ijhpm.8514. Epub 2025 May 28.
2
What are the costs associated with nausea and vomiting in pregnancy and hyperemesis gravidarum? A systematic review.妊娠恶心呕吐及妊娠剧吐的相关费用是多少?一项系统评价。
BMC Pregnancy Childbirth. 2025 Aug 1;25(1):807. doi: 10.1186/s12884-025-07921-5.
3
Socioeconomic inequality in financial hardship in accessing quality healthcare services in Ethiopia: a community-based cross-sectional study.

本文引用的文献

1
Clinical practice and costs of treating catheter-related infections with teicoplanin or vancomycin.替考拉宁或万古霉素治疗导管相关感染的临床实践与成本
Pharm Pract (Granada). 2006 Apr;4(2):68-73.
2
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.评估医疗保健中的成本效益:50,000 美元/QALY 阈值的历史。
Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):165-78. doi: 10.1586/14737167.8.2.165.
3
Methodological issues in the monetary valuation of benefits in healthcare.医疗保健中利益货币化的方法学问题。
埃塞俄比亚在获取优质医疗服务方面经济困难中的社会经济不平等:一项基于社区的横断面研究。
Front Public Health. 2025 Mar 26;13:1484671. doi: 10.3389/fpubh.2025.1484671. eCollection 2025.
4
Unit costs of health services provided at hospitals and health centres in two provinces of Zambia.赞比亚两个省份的医院和健康中心所提供医疗服务的单位成本。
GHM Open. 2024 Nov 30;4(2):69-79. doi: 10.35772/ghmo.2023.01023.
5
Estimating the indirect costs associated with adenocarcinoma or squamous cell carcinoma of the oesophagus in Switzerland: evidence from a cross-sectional survey.估算瑞士食管癌或食管鳞状细胞癌的间接成本:横断面调查证据
BMJ Open. 2025 Feb 22;15(2):e090401. doi: 10.1136/bmjopen-2024-090401.
6
Early evaluation of a screen-and-treat strategy using high-risk HPV testing for Uganda: Implications for screening coverage and treatment.早期评估乌干达采用高危型 HPV 检测的筛查-治疗策略:对筛查覆盖率和治疗的影响。
J Glob Health. 2024 Sep 20;14:04157. doi: 10.7189/jogh.14.04157.
7
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling.替代搜索方法在检索健康经济建模效用值中的实证检验。
Pharmacoeconomics. 2024 Nov;42(11):1255-1266. doi: 10.1007/s40273-024-01414-7. Epub 2024 Aug 6.
8
Research outcomes informing the selection of public health interventions and strategies to implement them: A cross-sectional survey of Australian policy-maker and practitioner preferences.研究结果为公共卫生干预措施和实施策略的选择提供信息:澳大利亚政策制定者和实践者偏好的横断面调查。
Health Res Policy Syst. 2024 May 14;22(1):58. doi: 10.1186/s12961-024-01144-4.
9
A mixed methods partner-focused cost and budget impact analysis to deploy implementation strategies for school-based prevention.一项以伙伴为重点的混合方法成本与预算影响分析,以部署基于学校的预防实施策略。
Implement Sci Commun. 2023 Nov 9;4(1):133. doi: 10.1186/s43058-023-00511-6.
10
Analyses of the return on investment of public health interventions: a scoping review and recommendations for future studies.公共卫生干预措施投资回报分析:范围综述及对未来研究的建议。
BMJ Glob Health. 2023 Aug;8(8). doi: 10.1136/bmjgh-2023-012798.
Expert Rev Pharmacoecon Outcomes Res. 2003 Dec;3(6):717-27. doi: 10.1586/14737167.3.6.717.
4
Health utility estimation.健康效用值评估。
Expert Rev Pharmacoecon Outcomes Res. 2002 Apr;2(2):99-108. doi: 10.1586/14737167.2.2.99.
5
Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature.药物带来的预期寿命增长:对相关文献的批判性评估
Expert Rev Pharmacoecon Outcomes Res. 2009 Aug;9(4):353-64. doi: 10.1586/erp.09.35.
6
Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.证据与价值:罕见病药物公共报销的要求——肿瘤学案例研究
Can J Clin Pharmacol. 2009 Summer;16(2):e273-81; discussion e282-4. Epub 2009 May 13.
7
Does preventive care save money? Health economics and the presidential candidates.预防性医疗保健能省钱吗?健康经济学与总统候选人。
N Engl J Med. 2008 Feb 14;358(7):661-3. doi: 10.1056/NEJMp0708558.
8
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.预算影响分析良好实践原则:ISPOR良好研究实践特别工作组——预算影响分析报告
Value Health. 2007 Sep-Oct;10(5):336-47. doi: 10.1111/j.1524-4733.2007.00187.x.
9
The increasingly complex fourth hurdle for pharmaceuticals.制药行业日益复杂的第四道难关。
Pharmacoeconomics. 2007;25(9):727-34. doi: 10.2165/00019053-200725090-00002.
10
Endometriosis: cost estimates and methodological perspective.子宫内膜异位症:成本估算与方法学视角
Hum Reprod Update. 2007 Jul-Aug;13(4):395-404. doi: 10.1093/humupd/dmm010.